Copyright
©The Author(s) 2021.
World J Stem Cells. Feb 26, 2021; 13(2): 139-154
Published online Feb 26, 2021. doi: 10.4252/wjsc.v13.i2.139
Published online Feb 26, 2021. doi: 10.4252/wjsc.v13.i2.139
Figure 1 Five major perks of mesenchymal stem cells therapies for pneumonia.
NO: Nitric oxide; COX2: Cyclooxygenase 2; TGF: Transforming growth factor; IL: Interleukin; EVs: Extracellular vesicles; PGE-2: Prostaglandin E2; SDF-1: Stromal cell-derived factor-1; VCAM-1: Vascular cell adhesion molecule-1; VLA-4: Very late antigen-4; MSCs: Mesenchymal stem cells; CXCR4: CXC chemokine receptor 4.
- Citation: Lam G, Zhou Y, Wang JX, Tsui YP. Targeting mesenchymal stem cell therapy for severe pneumonia patients. World J Stem Cells 2021; 13(2): 139-154
- URL: https://www.wjgnet.com/1948-0210/full/v13/i2/139.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i2.139